Sanofi’s Dupixent (dupilumab) has been cleared for NHS funding in Wales and Scotland in adolescents with severe eczema, also known as atopic dermatitis.
Take a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales in its once mighty diabetes franchise are sliding, while newer medicines such as its eczema and
Sanofi has agreed to buy cancer drugs firm Synthorx for around $2.5 billion, aiming to strengthen its immune-oncology drug pipeline and creating the possibility of new combination therapies
